How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

A study from the Arkansas Agricultural Experiment Station finds that GLP-1 medications, such as Ozempic and Wegovy, are ...

Real Housewives of New Jersey” star Jennifer Fessler didn’t follow her doctor’s advice when she started taking a GLP-1 weight ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

For the past few years, the buzz around drugs termed rather technically GLP-1 agonists has been deafening. That stands for glucagon-like peptide 1 receptor agonists, so we trust you won’t mind the ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

investigating the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on the incidence of atrial ... In addition ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...